208 related articles for article (PubMed ID: 24196395)
21. N17 Modifies mutant Huntingtin nuclear pathogenesis and severity of disease in HD BAC transgenic mice.
Gu X; Cantle JP; Greiner ER; Lee CY; Barth AM; Gao F; Park CS; Zhang Z; Sandoval-Miller S; Zhang RL; Diamond M; Mody I; Coppola G; Yang XW
Neuron; 2015 Feb; 85(4):726-41. PubMed ID: 25661181
[TBL] [Abstract][Full Text] [Related]
22. Foundation-directed therapeutic development in Huntington's disease.
Dominguez C; Munoz-Sanjuan I
J Med Chem; 2014 Jul; 57(13):5479-88. PubMed ID: 24432836
[TBL] [Abstract][Full Text] [Related]
23. Suppression of neurodegeneration and increased neurotransmission caused by expanded full-length huntingtin accumulating in the cytoplasm.
Romero E; Cha GH; Verstreken P; Ly CV; Hughes RE; Bellen HJ; Botas J
Neuron; 2008 Jan; 57(1):27-40. PubMed ID: 18184562
[TBL] [Abstract][Full Text] [Related]
24. Localized changes to glycogen synthase kinase-3 and collapsin response mediator protein-2 in the Huntington's disease affected brain.
Lim NK; Hung LW; Pang TY; Mclean CA; Liddell JR; Hilton JB; Li QX; White AR; Hannan AJ; Crouch PJ
Hum Mol Genet; 2014 Aug; 23(15):4051-63. PubMed ID: 24634145
[TBL] [Abstract][Full Text] [Related]
25. Autopsy-proven Huntington's disease with 29 trinucleotide repeats.
Kenney C; Powell S; Jankovic J
Mov Disord; 2007 Jan; 22(1):127-30. PubMed ID: 17115386
[TBL] [Abstract][Full Text] [Related]
26. [Gene silencing approaches for the treatment of Huntington's disease].
Merienne N; Déglon N
Med Sci (Paris); 2015 Feb; 31(2):159-67. PubMed ID: 25744262
[TBL] [Abstract][Full Text] [Related]
27. [Huntington disease. A review].
Bonilla E
Invest Clin; 2000 Jun; 41(2):117-41. PubMed ID: 10961047
[TBL] [Abstract][Full Text] [Related]
28. Adenovirus vector-based in vitro neuronal cell model for Huntington's disease with human disease-like differential aggregation and degeneration.
Dong X; Zong S; Witting A; Lindenberg KS; Kochanek S; Huang B
J Gene Med; 2012 Jul; 14(7):468-81. PubMed ID: 22700462
[TBL] [Abstract][Full Text] [Related]
29. Lack of huntingtin promotes neural stem cells differentiation into glial cells while neurons expressing huntingtin with expanded polyglutamine tracts undergo cell death.
Conforti P; Camnasio S; Mutti C; Valenza M; Thompson M; Fossale E; Zeitlin S; MacDonald ME; Zuccato C; Cattaneo E
Neurobiol Dis; 2013 Feb; 50():160-70. PubMed ID: 23089356
[TBL] [Abstract][Full Text] [Related]
30. Triplet repeat mutation length gains correlate with cell-type specific vulnerability in Huntington disease brain.
Shelbourne PF; Keller-McGandy C; Bi WL; Yoon SR; Dubeau L; Veitch NJ; Vonsattel JP; Wexler NS; ; Arnheim N; Augood SJ
Hum Mol Genet; 2007 May; 16(10):1133-42. PubMed ID: 17409200
[TBL] [Abstract][Full Text] [Related]
31. Quantitative proteomic analysis of induced pluripotent stem cells derived from a human Huntington's disease patient.
Chae JI; Kim DW; Lee N; Jeon YJ; Jeon I; Kwon J; Kim J; Soh Y; Lee DS; Seo KS; Choi NJ; Park BC; Kang SH; Ryu J; Oh SH; Shin DA; Lee DR; Do JT; Park IH; Daley GQ; Song J
Biochem J; 2012 Sep; 446(3):359-71. PubMed ID: 22694310
[TBL] [Abstract][Full Text] [Related]
32. 14-3-3zeta is indispensable for aggregate formation of polyglutamine-expanded huntingtin protein.
Omi K; Hachiya NS; Tanaka M; Tokunaga K; Kaneko K
Neurosci Lett; 2008 Jan; 431(1):45-50. PubMed ID: 18078716
[TBL] [Abstract][Full Text] [Related]
33. Marked differences in neurochemistry and aggregates despite similar behavioural and neuropathological features of Huntington disease in the full-length BACHD and YAC128 mice.
Pouladi MA; Stanek LM; Xie Y; Franciosi S; Southwell AL; Deng Y; Butland S; Zhang W; Cheng SH; Shihabuddin LS; Hayden MR
Hum Mol Genet; 2012 May; 21(10):2219-32. PubMed ID: 22328089
[TBL] [Abstract][Full Text] [Related]
34. Personalized gene silencing therapeutics for Huntington disease.
Kay C; Skotte NH; Southwell AL; Hayden MR
Clin Genet; 2014 Jul; 86(1):29-36. PubMed ID: 24646433
[TBL] [Abstract][Full Text] [Related]
35. Drugging unconventional targets: insights from Huntington's disease.
Yu S; Liang Y; Palacino J; Difiglia M; Lu B
Trends Pharmacol Sci; 2014 Feb; 35(2):53-62. PubMed ID: 24388390
[TBL] [Abstract][Full Text] [Related]
36. Human embryonic stem cell models of Huntington disease.
Niclis J; Trounson AO; Dottori M; Ellisdon A; Bottomley SP; Verlinsky Y; Cram D
Reprod Biomed Online; 2009 Jul; 19(1):106-13. PubMed ID: 19573298
[TBL] [Abstract][Full Text] [Related]
37. Targeting mutant huntingtin for the development of disease-modifying therapy.
Appl T; Kaltenbach L; Lo DC; Terstappen GC
Drug Discov Today; 2012 Nov; 17(21-22):1217-23. PubMed ID: 22772050
[TBL] [Abstract][Full Text] [Related]
38. Oxidative stress causes DNA triplet expansion in Huntington's disease mouse embryonic stem cells.
Jonson I; Ougland R; Klungland A; Larsen E
Stem Cell Res; 2013 Nov; 11(3):1264-71. PubMed ID: 24041806
[TBL] [Abstract][Full Text] [Related]
39. HD CAGnome: a search tool for huntingtin CAG repeat length-correlated genes.
Galkina EI; Shin A; Coser KR; Shioda T; Kohane IS; Seong IS; Wheeler VC; Gusella JF; Macdonald ME; Lee JM
PLoS One; 2014; 9(4):e95556. PubMed ID: 24751919
[TBL] [Abstract][Full Text] [Related]
40. Experimental models of HD and reflection on therapeutic strategies.
Kim J; Bordiuk OL; Ferrante RJ
Int Rev Neurobiol; 2011; 98():419-81. PubMed ID: 21907096
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
